Management

VIEW OUR PORTFOLIO

p019
p015




p017
p008


image_print

Adrian Adams – Chief Executive Officer

adrian-sMr. Adams is Chief Executive Officer and a Director of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since June 1, 2015. Prior to joining the company, Mr. Adams served as Chief Executive Officer and President of Auxilium Pharmaceuticals, Inc. from December 2011 until its acquisition by Endo International plc in January 2015 for $2.6 billion. Under his leadership, Auxilium transformed into a men’s healthcare company and broadened its portfolio from two to twelve through the strategic corporate acquisition of Actient Holding LLC and product in-licensing. Prior to joining Auxilium, Mr. Adams served as Chairman and Chief Executive Officer of Neurologix, Inc., a company focused on development of multiple innovative gene therapy development programs. Before Neurologix, Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc., where he oversaw the commercialization and development of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader Merck & Co., Inc. in May 2011 for $430 million.Prior to Inspire, Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. from December 2006 until its acquisition by Dainippon Sumitomo Pharma Co in February 2010 for $2.6 billion. Under his leadership, Sepracor conducted multiple strategic corporate development activities, including the in-licensing of seven products and out-licensing deals with two major pharmaceutical companies, prior to its acquisition by Dainippon Sumitomo Pharma Co.

Prior to joining Sepracor, Mr. Adams was President and Chief Executive Officer of Kos Pharmaceuticals, Inc. from 2002 until the acquisition of the company by Abbott Laboratories in December 2006 for $3.7 billion. During his tenure he led the transformation of Kos into a fully integrated and profitable pharmaceutical company with annual revenues approaching $1 billion. During his 30 years of experience, Mr. Adams also held general management and senior marketing positions at ICI (now part of AstraZeneca), SmithKline Beecham and Novartis. He has extensive international and national experience and has been instrumental in launching major global brands in addition to driving successful corporate development activities encapsulating financing, product and company acquisitions, in-licensing and company M&A activities.

Mr. Adams graduated from the Royal Institute of Chemistry at Salford University in the U.K. Mr. Adams serves as Chairman of the Board of AcelRx Pharmaceuticals and recently served as a director of Amylin Pharmaceuticals.

Andrew I. Koven – President and Chief Business Officer

andrew-sMr. Koven is President and Chief Business Officer of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since June 1, 2015. Mr. Koven has over 26 years of experience practicing law, most of which has been in the pharmaceutical industry. Prior to joining the company, Mr. Koven served as Executive Vice President, Chief Administrative Officer, and General Counsel and Secretary of Auxilium Pharmaceuticals, Inc. from February 2012 until its acquisition by Endo International plc in January 2015. In his role, Mr. Koven was responsible for Auxilium’s legal functions, government affairs and technical operations. Prior to Auxilium, Mr. Koven served as President and Chief Administrative Officer of Neurologix, Inc. Prior to that, Mr. Koven was Executive Vice President and Chief Administrative and Legal Officer at Inspire Pharmaceuticals, Inc., where he oversaw all matters related to legal, quality and compliance, corporate development and licensing and technical operations prior to the strategic acquisition of the company by Merck & Co. From 2007 to 2010 Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary at Sepracor Inc. before its acquisition by Dainippon Sumitomo Pharma Co in 2009. Before joining Sepracor, Mr. Koven was Executive Vice President, General Counsel and Corporate Secretary at Kos Pharmaceuticals, Inc., where he oversaw the company’s legal, compliance and quality assurance departments until the acquisition of the company by Abbott Laboratories in 2006.

Mr. Koven began his career in the pharmaceutical industry as an Assistant General Counsel at Warner- Lambert Company from 1993 to 2000, followed by his role as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003. From 1986 to 1992 he was a corporate associate at Cahill, Gordon & Reindel in New York.

Eric L. Trachtenberg – General Counsel, Chief Compliance Officer & Corporate Secretary

Mr. Trachtenberg serves as General Counsel, Chief Compliance Officer and Corporate Secretary of Aralez Pharmaceuticals Inc. since February 5, 2016. Previously, Mr. Trachtenberg served as Deputy General Counsel of POZEN Inc., the company’s predecessor, which he joined on June 22, 2015. Mr. Trachtenberg has extensive experience practicing law, including over ten years in the pharmaceutical industry. Mr. Trachtenberg most recently served as Deputy General Counsel at Auxilium Pharmaceuticals, Inc., from 2012 through its acquisition by Endo Pharmaceuticals in February 2015. Prior to Auxilium, he was Vice President, General Counsel and Corporate Secretary of Enobia Pharma, Inc. and managed all legal aspects of Enobia’s sale to Alexion Pharmaceuticals. Prior to that, Mr. Trachtenberg served as Vice President and Associate General Counsel of Sepracor Inc. and remained in that position with Sunovion Pharmaceuticals Inc. following the acquisition of Sepracor by Dainippon Sumitomo Pharma. Mr. Trachtenberg also held a Senior Counsel position at Kos Pharmaceuticals, Inc. before its acquisition by Abbott. Mr. Trachtenberg began his career as an Associate at Blank Rome LLP.

He holds a Bachelor of Science degree in Management from Tulane University and a Juris Doctorate and Master of Business Administration degree from Temple University.

James Tursi, M.D. – Chief Medical Officer

Dr. James Tursi is Chief Medical Officer of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since October 1, 2015. Dr. Tursi has over 11 years of extensive experience developing pharmaceuticals across a number of therapeutic areas. Prior to joining the company, he served as Chief Medical Officer of Innocoll AG where he was responsible for managing all clinical research and development, medical affairs and safety activities. Prior to joining Innocoll, Dr. Tursi served as Chief Medical Officer at Auxilium Pharmaceuticals Inc. from 2011 to 2015, where he previously held the position of Vice President of Clinical Research & Development from 2009 to 2011. He was responsible for oversight of clinical and nonclinical development programs, clinical operations, medical affairs and global safety activities. Dr. Tursi served as the clinical medical safety lead for all regulatory agency interactions with the FDA, Europe and Canada. Prior to Auxilium, he served as Director of Medical Affairs for GlaxoSmithKline Biologicals from 2006 to 2009 and directed all medical affairs responsibilities for cervical cancer vaccines in North America. Dr. Tursi entered the pharmaceutical industry in 2004 as a Medical Director for Procter and Gamble Pharmaceuticals until 2006. He worked on several products and therapeutic areas, which included female sexual dysfunction, overactive bladder, and osteoporosis. His responsibilities included clinical development and medical affairs. Dr. Tursi was a board certified OB/GYN and practiced medicine and surgery for over 10 years.

Dr. Tursi received his doctor of medicine degree from the Medical College of Pennsylvania and completed his residency training at the Johns Hopkins Hospital. Dr. Tursi serves as a member of the board of directors of Agile Therapeutics.

Jennifer L. Armstrong – Executive Vice President, Human Resources and Administration

jennifer-sMs. Armstrong is Executive Vice President of Human Resources and Administration of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since June 22, 2015. Ms. Armstrong has over 15 years of experience in the Human Resources field, primarily in the biotech industry. Prior to joining the company, Ms. Armstrong served as Senior Vice President of Human Resources at Auxilium Pharmaceuticals, Inc. Prior to that, she served at Senior Vice President of Human Resources and Corporate Communications at Genaera Corporation. During her decade long tenure at Genaera, Ms. Armstrong was responsible for all facets of Human Resources, including working directly with the Compensation Committee on executive and equity compensation strategies. She also was responsible for investor and public relations while overseeing the IT and facilities functions.

Ms. Armstrong holds a Master’s degree in Arts Administration and a Bachelors degree in Corporate Communications, both from Drexel University.

Mark A. Glickman – Chief Commercial Officer

mark-sMr. Glickman is Chief Commercial Officer of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since June 22, 2015. Mr. Glickman has over 20 years of experience in pharmaceutical sales and operations, with expertise in a variety of fields including sales turnarounds, global product introductions and organizational expansions. Prior to joining the company, Mr. Glickman served as Executive Vice President of Sales and Marketing for Auxilium Pharmaceuticals. Prior to that, he served as Vice President in the medical device division at Otsuka America Pharmaceutical, Inc. At Otsuka, he helped to reinvigorate the company’s sales and increase its business by 50% over two years, while also spearheading quality improvement initiatives and playing a critical role in new regulatory filings. Prior to Otsuka, Mr. Glickman served as Senior Vice President of Sales and Marketing at Oscient Pharmaceuticals Corp., during which time he completed a successful turnaround of the company’s commercial strategy, driving a significant increase in sales. Before joining Oscient, Mr. Glickman served as Vice President of Sales at Bayer Healthcare’s Diabetes Care Division. From 2001 to 2007 he played a major role in helping to build the commercial organization at Kos Pharmaceuticals and held various positions including Director of Marketing, Regional Sales Director and Vice President of Sales. Mr. Glickman started his pharmaceutical career at Bristol-Myers Squibb where he was responsible for the marketing of cardiovascular products, including the blockbuster Plavix.

Mr. Glickman holds a Master of Business Administration degree from New York University.

Scott J. Charles – Chief Financial Officer

scott-sMr. Charles is Chief Financial Officer of Aralez Pharmaceuticals Inc. Previously, Mr. Charles served as Senior Vice President of Finance of POZEN Inc., the company’s predecessor, which he joined on July 27, 2015.  Mr. Charles has over 19 years of experience with a record of accomplishment across a spectrum of financial operations in public and private environments. Prior to joining the company, he most recently served as the Vice President of Finance and Treasurer at Ikaria, Inc., a critical care pharmaceutical company based in Hampton, New Jersey with annual revenues in excess of $400 million. Mr. Charles played a lead role in the spin-off of Ikaria’s R&D operations and sale of its commercial business to a private equity firm in 2014 for $1.6B and then to Mallinckrodt in April 2015 for $2.3B. Mr. Charles also successfully helped raise over $3B through numerous capital market transactions. While at Ikaria, Mr. Charles had the opportunity to lead all of the finance functions. Prior to that, Mr. Charles held several senior finance roles of increasing responsibility, culminating as the Vice President of Finance and Treasurer at Reliant Pharmaceuticals, Inc. Mr. Charles played an integral role in the company’s M&A process that resulted in the successful sale of Reliant to GlaxoSmithKline for $1.6B in 2007. He was also instrumental in closing several business development transactions, including the acquisition of Lovaza, a product that grew to over $1B in annual revenues. Prior to that he was a Manager of Assurance and Business Advisory Services at Arthur Andersen, LLP.

He holds a Bachelor of Science degree in Business Administration from Bucknell University and is a Certified Public Accountant.